Clovis Oncology — Shaping the Future of Targeted Radionuclide Therapies

Clovis is committed to being a leader in the development of targeted radionuclide therapies and realizing their potential for patients.

Seeking to Lead in targeted radionuclide therapy development

Targeted radionuclide therapies are an emerging class of therapies with potential to be applied across many solid tumor types, and Clovis is pursuing a broad and accelerated clinical development program to support this potential new pillar in oncology drug development. FAP-2286, the lead candidate in Clovis Oncology’s targeted radionuclide therapy development pipeline, binds to fibroblast activation protein, or FAP, with the potential to offer a “pan-cancer” approach to treating tumors. Clovis also has global rights to three additional targeted radionuclide therapy candidates currently in discovery. Clovis, together with licensing partner 3B Pharmaceuticals, is highly committed to this emerging field in oncology drug development and we are building the expertise and infrastructure to support the global development and distribution of FAP-2286, and future development of compounds for targeted radionuclide therapies.

Clovis is committed to building the expertise and infrastructure to support a broad development pipeline.

Clovis is committed to building the expertise and infrastructure to support a broad development pipeline.

Clovis Oncology is on a Mission to Advance the Fight Against Cancer

At Clovis Oncology, we are committed to realizing the promise of precision medicine for cancer. We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient. Our mission will be achieved by excelling at the science, development and commercialization of drugs that will further advance the treatment of cancer.

Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

References

[1] Information on File. Clovis Oncology. Year of information 2021.

[8] Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ. Regulation and heteromeric structure of the ­fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993 Jul 15;53(14):3327-35. PMID: 8391923.

[9] Garin-Chesa, P.. Old. L. J.. and Rettig. W. i. Cell surface glycoprotein of reactive stromal ­fibroblasts as a potential antibody-target in human epithelial cancers. Proc. Nati. Acad. Sci. USA, 87: 7235-7239, 1990.

[10] Information on File. Clovis Oncology. Year of information 2019.

[11]. Zboralski, D, et al. Preclinical Evaluation of FAP-2286, a Peptide-targeted Radionuclide Therapy to Fibroblast Activation Protein. Poster or Paper presented at: ESMO Virtual Conference 2020; 19-21 September 2020; Virtual Conference.

[12] Brennen, W Nathaniel et al. Rationale behind targeting fi­broblast activation protein-expressing carcinoma-associated fi­broblasts as a novel chemotherapeutic strategy. Molecular cancer therapeutics vol. 11,2 (2012): 257-66. doi:10.1158/1535-7163.MCT-11-0340.

[17] Jeelani, S et al. “Theranostics: A treasured tailor for tomorrow.” Journal of pharmacy & bioallied sciences vol. 6,Suppl 1 (2014): S6-8. doi:10.4103/0975-7406.137249.

[19] Information on File. Clovis Oncology. Year of information 2020.

[20]. Information on File. Clovis Oncology. Year of information 2021.

[21] Information on File. Clovis Oncology. Year of information 2019.

[30] Baghban, R., Roshangar, L., Jahanban-Esfahlan, R. et al. (2020). Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal, 18:59. https://doi.org/10.1186/s12964-020-0530-4.

[31] National Cancer Institute. (2021). Definition of Radionuclide. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/radionuclide (Accessed: May 21, 2021).

[32] Science Direct. (2021). Lutetium 177 Overview. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/lutetium-177 (Accessed May 21, 2021).

[33] Banerjee, S. R., & Pomper, M. G. (2013). Clinical applications of Gallium-68. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 76, 2–13. https://doi.org/10.1016/j.apradiso.2013.01.039.